Navigation Links
Surveyed Oncologists Expect to Prescribe Provenge to about Half of Their Prostate Cancer Patients if the Vaccine is Approved
Date:7/28/2009

WALTHAM, Mass., July 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Dendreon's Provenge receives regulatory approval, surveyed oncologists expect to prescribe Provenge to 54 percent of patients with asymptomatic hormone refractory metastatic prostate cancer. Due to the side effects associated with currently available chemotherapy, most oncologists recommend that men who have stopped responding to hormone therapy wait for the development of symptoms before starting chemotherapy.

The new Physician & Payer Forum report entitled Clinician and Payer Attitudes Toward Emerging Cancer Vaccines for Prostate Cancer, Lung Cancer, and Glioma finds that clinicians are willing to prescribe Provenge to patients in the absence of symptoms. The report also finds that three-quarters of surveyed oncologists and urologists consider Provenge a major breakthrough in the treatment of prostate cancer. Additionally, 89 percent of surveyed urologists expect to prescribe Provenge for prostate cancer.

"Treatment rates for advanced prostate cancer will be boosted by an effective vaccine which also carries a benign side effect profile," said Decision Resources Analyst Marcus Hoyle. "Surveyed clinicians indicate they are very encouraged by the fact that, in a Phase III clinical trial, Provenge demonstrated an improvement in median overall survival in prostate cancer patients."

In addition to Provenge, other therapeutic vaccines in development for cancer include Merck KGaA's Stimuvax for non-small-cell lung cancer and Celldex Therapeutics/Pfizer's CDX-110 for glioblastoma multiforme (glioma). Surveyed experts consider both drugs to be the most promising therapeutic vaccines for the treatment of these two diseases, owing to an impressive effect on overall survival
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibbs Orencia
2. For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
3. For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
4. Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting
5. Surveyed Psychiatrists and PCPs Expect to Increase Their First-Line Use of SNRIs Over the Next Two Years for the Treatment of Generalized Anxiety Disorder
6. For Alzheimers Disease, Surveyed Neurologists Identify a Therapys Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions
7. For Bipolar Depression, Surveyed Experts Indicate That Current and Emerging Therapies Have No Advantage Over Seroquel in Decreasing the Severity of Symptoms
8. Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer
9. Surveyed Specialists Foresee Greater Use of Parenteral Outpatient Therapy for the Treatment of Osteomyelitis
10. For Atrial Fibrillation, Surveyed Experts Indicate That Multaq, Celivarone and ATI-2042 Have Advantages Over Propafenone in the Maintenance of Normal Sinus Rhythm
11. For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Access to generic ... patients will stick with their drug treatment, a new ... women with hormone receptor-positive breast cancer can reduce recurrence ... Hershman, an associate professor of epidemiology at Columbia University ... hospital news release. "However, work by our ...
(Date:10/31/2014)... Alan Mozes HealthDay ... In the world of 21st-century medicine, organ transplantation is nothing ... followed by the first liver transplant in 1963 and the ... even managed the transplantation of a patient,s entire face. ... entire human eye. But if one team of U.S. scientists ...
(Date:10/31/2014)... Each year, people across the United States spend an ... friends, which costs $522 billion, according to new research. ... on the time and wages that caregivers give up ... in daily activities. The study authors said the significant ... workplace flexibility policies. "Our findings provide a new ...
(Date:10/30/2014)... at Albert Einstein College of Medicine ... will present their latest aging research at ... Scientific Meeting. Topics include the identification of a ... cognitive impairment and the cellular biology of aging. ... in Washington, D.C., "Einstein-Montefiore has distinguished itself in ...
(Date:10/30/2014)... Tanaka and her research group at the DFG Research ... at the TU Dresden (CRTD) demonstrated for the first ... spinal cord in three dimensions from mouse embryonic stem ... dorsal interneurons along the dorsal/ventral axis was observed., This ... " Stem Cell Reports " on 30.10.2014 ., ...
Breaking Medicine News(10 mins):Health News:Generic Drugs May Help Breast Cancer Patients Stick to Therapy 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 3Health News:'Informal Care' for Older Americans Tops $500B Annually, Study Finds 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2
... 30 Keck Graduate Institute (KGI) ... begin in January 2010, for those with an undergraduate degree ... skills before applying to medical school. , "We,re excited to ... medical professional," says Sheldon M. Schuster, PhD, KGI,s president. "Whether ...
... BEIJING, Sept. 30 /PRNewswire-Asia/ -- Sinovac Biotech ... products in China, announced today that,Sinovac has received its ... Ministry of Industry and Information Technology of the People,s,Republic ... purchase order,Sinovac is required to produce an additional 3 ...
... America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord ... ) focused on bringing the life saving potential ... nationwide and internationally, said today that it is opening ... laboratory in Las Vegas, as planned, the first ...
... National Breast Cancer Awareness Month and Topcor is introducing a ... October 5th, "Clipa for a Cure" is a special edition ... donate 10% of the retail price of every pink Clipa ... Society, breast cancer is the second leading cause of cancer ...
... Americans lack confidence that healthcare reform will deliver ... a survey released today by Thomson Reuters. , Forty-one ... make healthcare more affordable. When sorted by political ... divisions along party lines: 72 percent of Democrats said ...
... , LUDWIGSHAFEN, Germany, September 30 ... to cope with all the sustenance,we shove into it every ... the hardest substance that the human body produces. It consists ... questions of our Podcast listeners on Chemistry in our,everyday life. ...
Cached Medicine News:Health News:KGI Establishes Post Baccalaureate Premedical Program 2Health News:Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 2Health News:Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 3Health News:Cord Blood America Opens Las Vegas Cryogenic Laboratory; Consolidates Offices in Nevada 2Health News:Cord Blood America Opens Las Vegas Cryogenic Laboratory; Consolidates Offices in Nevada 3Health News:'Clipa for a Cure': New Pink Instant Handbag Hanger Benefits Breast Cancer Research 2Health News:Thomson Reuters Survey: Americans Skeptical That Healthcare Reform Will Improve Quality or Affordability 2Health News:BASF Podcast: The Chemical Reporter - Why Does Fluoride Make Your Teeth Hard? 2Health News:BASF Podcast: The Chemical Reporter - Why Does Fluoride Make Your Teeth Hard? 3
(Date:10/31/2014)...  Zebra Imaging, Inc., the world,s foremost provider ... strategic partnership with the Zygote Media Group Inc., ... biomedical models for animation and visual effects, to ... maintains the world,s most comprehensive library of accurate ... development of high-end solid 3D anatomy models for ...
(Date:10/31/2014)... October 31, 2014 Oramed ... pharmaceutical company focused on the development of oral ... host a conference call to discuss the clinical ... ORMD-0801, the company,s proprietary oral insulin capsules, to ... 2014 at 10:00 a.m. Eastern time. ...
(Date:10/31/2014)... 2014  Zacks.com announces the list of stocks featured in the ... latest news and events impacting stocks and the financial markets. Stocks ... - Free Report ), Celgene (Nasdaq: CELG ... - Free Report ), Market Vectors Biotech ETF (AMEX: ... (AMEX: XBI - Free Report ). ...
Breaking Medicine Technology:Zebra Imaging and Zygote Media Partner to Bring 3D Visualization to the Medical Community 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7
... Knopp Neurosciences Inc. ("Knopp"),today announced the ... of KNS-760704, a,small molecule therapy in development ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ) ... in healthy volunteers is being closely followed ...
... planning,use prevents over one million HIV-positive births worldwide ... the number of infants born with HIV,according to ... for Women With HIV," published by the INFO ... Center for Communication Programs. Women account for ...
Cached Medicine Technology:Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program 2Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program 3Hopkins Report: Focusing on Family Planning Lessens HIV Impact 2Hopkins Report: Focusing on Family Planning Lessens HIV Impact 3
This cannula's patented tip allows the simultaneous infusion of cardioplegia and aspiration of air from the aorta...
This cannula features a PVC body, auto inflatable smooth cuff, pressure monitoring line with integral stopcock....
...
... Select CAP® cannulae provides a simple ... readings. An innovative combination of aortic ... line, the Select CAP® can provide ... arterial pressure readings on which you ...
Medicine Products: